AbbVie | ABBV - Selling And Administration Expenses


AbbVie reported $3.84B in Selling and Administration Expenses for its fiscal quarter ending in September of 2026.





Selling And Administration Expenses Change Date
AbbVie USD 3.84B 205M Sep/2026
Abbott USD 4.27B 669M Sep/2026
ALKERMES USD 190.54M 6.1M Sep/2026
Amgen USD 1.68B 40M Sep/2026
AstraZeneca USD 4.07B 1.73B Sep/2026
Biogen USD 752M 42.3M Sep/2026
BioMarin Pharmaceutical USD 333.64M 61.91M Sep/2026
Bristol-Myers Squibb USD 1.7B 127M Sep/2026
Coherus Biosciences USD 15M 6.26M Dec/2025
Eisai JPY 120.4B 5.58B Sep/2026
Eli Lilly USD 3.12B 305M Sep/2026
Gilead Sciences USD 1.52B 70M Jun/2026
GlaxoSmithKline GBP 2.16B 39M Sep/2026
J&J USD 6.25B 168M Sep/2026
Medtronic 3.2B 141M Jun/2026
Merck USD 2.86B 25M Sep/2026
Neurocrine Biosciences USD 366.3M 16.8M Sep/2026
Novartis USD 3.08B 163M Sep/2026
Pacira USD 950.8M 858.99M Sep/2026
Perrigo USD 271.7M 3.01B Sep/2026
Pfizer USD 3.28B 132M Sep/2026
Regeneron Pharmaceuticals USD 662.1M 14.4M Jun/2026
Roche Holding CHF 6.37B 908M Jun/2026
Sanofi EUR 2.31B 325M Sep/2026
UCB EUR 1.47B 193M Dec/2025
Ultragenyx Pharmaceutical USD 97M 9M Sep/2026
United Therapeutics USD 184.1M 22.6M Sep/2026
Vertex Pharmaceuticals USD 556.3M 25.9M Sep/2026
Zoetis USD 582M 10M Sep/2026